Detalles de la búsqueda
1.
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Leukemia
; 32(3): 788-800, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28852199
2.
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Leukemia
; 32(12): 2731, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30232463
Resultados
1 -
2
de 2
1
Próxima >
>>